1|Page
NURS 6521 - ADVANCED PHARMACOLOGY
COMPLETE EXAM BANK: 200+ QUESTIONS
WITH ANSWERS & RATIONALES EDITION: 2026-
2027 | NCLEX/HESI/ATI STYLE | HIGH-YIELD
CONTENT**
---
# TABLE OF CONTENTS
1. **Pharmacokinetics & Pharmacodynamics** (Questions 1-20)
2. **Autonomic Nervous System Drugs** (Questions 21-35)
3. **Cardiovascular Pharmacology** (Questions 36-60)
4. **Anticoagulation & Hematology** (Questions 61-80)
5. **Antibiotics & Antimicrobials** (Questions 81-110)
6. **Psychopharmacology** (Questions 111-135)
7. **Neurologic & Pain Management** (Questions 136-155)
8. **Endocrine Pharmacology** (Questions 156-180)
9. **Immunology & Oncology** (Questions 181-195)
10. **Special Populations & Toxicology** (Questions 196-210)
---
,2|Page
# SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
---
### Question 1
A 55-year-old male with hepatic cirrhosis (Child-Pugh Class B) is
prescribed a medication that undergoes extensive first-pass metabolism.
The APRN understands that which pharmacokinetic alteration is most
likely to occur?
A. Increased bioavailability due to reduced hepatic extraction
B. Decreased half-life due to increased volume of distribution
C. Reduced protein binding leading to decreased free drug fraction
D. Enhanced first-pass effect requiring higher oral doses
**Answer: A**
**Rationale:** First-pass metabolism occurs primarily in the liver. In
hepatic cirrhosis, portal blood flow is reduced and hepatocyte function is
impaired, leading to **decreased first-pass metabolism**. This results in
**increased bioavailability** of orally administered drugs that normally
undergo extensive hepatic extraction (e.g., propranolol, morphine,
lidocaine). The APRN must reduce oral doses to prevent toxicity. Option
,3|Page
B is incorrect because half-life typically increases in liver disease.
Option C is partially true (protein binding decreases) but this increases
free drug fraction, not decreases. Option D is opposite of what occurs.
---
### Question 2
A patient with heart failure is receiving digoxin. The APRN notes that
the patient also takes spironolactone. Which pharmacokinetic interaction
is most concerning?
A. Spironolactone increases renal clearance of digoxin
B. Spironolactone displaces digoxin from protein binding sites
C. Spironolactone may falsely elevate digoxin serum levels in assays
D. Spironolactone induces CYP3A4, decreasing digoxin levels
**Answer: C**
**Rationale:** Spironolactone and its metabolites (especially
canrenone) interfere with **immunoassays** used to measure digoxin
levels, causing **falsely elevated readings**. This can lead to
inappropriate dose reductions and underdosing. The APRN must be
aware of this assay interaction and consider using alternative testing
methods (e.g., LC-MS/MS) if available. Option A is incorrect;
spironolactone does not significantly affect digoxin renal clearance.
, 4|Page
Option B is not clinically significant. Option D is incorrect; digoxin is
not metabolized by CYP3A4 (it is renally excreted).
---
### Question 3
A 45-year-old female with a urinary tract infection is prescribed
nitrofurantoin. She asks why she must take the medication with food.
The APRN explains that food enhances absorption by which
mechanism?
A. Increasing gastric pH to prevent acid degradation
B. Slowing gastric emptying to increase dissolution time
C. Competing for P-glycoprotein efflux transporters
D. Providing dietary fats that serve as a drug carrier
**Answer: B**
**Rationale:** Nitrofurantoin absorption is **enhanced by food**
because food **slows gastric emptying**, allowing more time for
dissolution and absorption in the small intestine. This also reduces
gastrointestinal side effects. Option A is incorrect; nitrofurantoin is not
acid-labile. Option C is a mechanism for some drugs (e.g., digoxin with
quinidine) but not nitrofurantoin. Option D is incorrect; nitrofurantoin
does not require fats for absorption.
NURS 6521 - ADVANCED PHARMACOLOGY
COMPLETE EXAM BANK: 200+ QUESTIONS
WITH ANSWERS & RATIONALES EDITION: 2026-
2027 | NCLEX/HESI/ATI STYLE | HIGH-YIELD
CONTENT**
---
# TABLE OF CONTENTS
1. **Pharmacokinetics & Pharmacodynamics** (Questions 1-20)
2. **Autonomic Nervous System Drugs** (Questions 21-35)
3. **Cardiovascular Pharmacology** (Questions 36-60)
4. **Anticoagulation & Hematology** (Questions 61-80)
5. **Antibiotics & Antimicrobials** (Questions 81-110)
6. **Psychopharmacology** (Questions 111-135)
7. **Neurologic & Pain Management** (Questions 136-155)
8. **Endocrine Pharmacology** (Questions 156-180)
9. **Immunology & Oncology** (Questions 181-195)
10. **Special Populations & Toxicology** (Questions 196-210)
---
,2|Page
# SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
---
### Question 1
A 55-year-old male with hepatic cirrhosis (Child-Pugh Class B) is
prescribed a medication that undergoes extensive first-pass metabolism.
The APRN understands that which pharmacokinetic alteration is most
likely to occur?
A. Increased bioavailability due to reduced hepatic extraction
B. Decreased half-life due to increased volume of distribution
C. Reduced protein binding leading to decreased free drug fraction
D. Enhanced first-pass effect requiring higher oral doses
**Answer: A**
**Rationale:** First-pass metabolism occurs primarily in the liver. In
hepatic cirrhosis, portal blood flow is reduced and hepatocyte function is
impaired, leading to **decreased first-pass metabolism**. This results in
**increased bioavailability** of orally administered drugs that normally
undergo extensive hepatic extraction (e.g., propranolol, morphine,
lidocaine). The APRN must reduce oral doses to prevent toxicity. Option
,3|Page
B is incorrect because half-life typically increases in liver disease.
Option C is partially true (protein binding decreases) but this increases
free drug fraction, not decreases. Option D is opposite of what occurs.
---
### Question 2
A patient with heart failure is receiving digoxin. The APRN notes that
the patient also takes spironolactone. Which pharmacokinetic interaction
is most concerning?
A. Spironolactone increases renal clearance of digoxin
B. Spironolactone displaces digoxin from protein binding sites
C. Spironolactone may falsely elevate digoxin serum levels in assays
D. Spironolactone induces CYP3A4, decreasing digoxin levels
**Answer: C**
**Rationale:** Spironolactone and its metabolites (especially
canrenone) interfere with **immunoassays** used to measure digoxin
levels, causing **falsely elevated readings**. This can lead to
inappropriate dose reductions and underdosing. The APRN must be
aware of this assay interaction and consider using alternative testing
methods (e.g., LC-MS/MS) if available. Option A is incorrect;
spironolactone does not significantly affect digoxin renal clearance.
, 4|Page
Option B is not clinically significant. Option D is incorrect; digoxin is
not metabolized by CYP3A4 (it is renally excreted).
---
### Question 3
A 45-year-old female with a urinary tract infection is prescribed
nitrofurantoin. She asks why she must take the medication with food.
The APRN explains that food enhances absorption by which
mechanism?
A. Increasing gastric pH to prevent acid degradation
B. Slowing gastric emptying to increase dissolution time
C. Competing for P-glycoprotein efflux transporters
D. Providing dietary fats that serve as a drug carrier
**Answer: B**
**Rationale:** Nitrofurantoin absorption is **enhanced by food**
because food **slows gastric emptying**, allowing more time for
dissolution and absorption in the small intestine. This also reduces
gastrointestinal side effects. Option A is incorrect; nitrofurantoin is not
acid-labile. Option C is a mechanism for some drugs (e.g., digoxin with
quinidine) but not nitrofurantoin. Option D is incorrect; nitrofurantoin
does not require fats for absorption.
